Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Guardado en:
Autores principales: | William L Redmond, Walter J Urba, John Cha, Yoshinobu Koguchi, Brendan D Curti, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, Brian D Piening |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/76e873d352b1483a8641f7e468b7a2f9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of ipilimumab in the treatment of melanoma
por: Acharya UH, et al.
Publicado: (2013) -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Alexander N Shoushtari, et al.
Publicado: (2021) -
Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021) -
IgA Nephropathy Secondary to Ipilimumab Use
por: Sean C. Dougherty, et al.
Publicado: (2021) -
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021)